BAY 1024767 blocks androgen receptor mutants found in castration-resistant prostate cancer patients

about

BAY 1024767 blocks androgen receptor mutants found in castration-resistant prostate cancer patients

Item

http://www.wikidata.org/entity/Q36905832

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

BAY 1024767 blocks androgen re ...... stant prostate cancer patients

@en

type

Item

label

BAY 1024767 blocks androgen re ...... stant prostate cancer patients

@en

prefLabel

BAY 1024767 blocks androgen re ...... stant prostate cancer patients

@en

P1476

BAY 1024767 blocks androgen re ...... stant prostate cancer patients

@en

P2093

Arwed Cleve

http://www.w3.org/2001/XMLSchema#string

Bernard Haendler

http://www.w3.org/2001/XMLSchema#string

Carsten Stephan

http://www.w3.org/2001/XMLSchema#string

Dominik Mumberg

http://www.w3.org/2001/XMLSchema#string

Franz von Nussbaum

http://www.w3.org/2001/XMLSchema#string

Hortensia Faus

http://www.w3.org/2001/XMLSchema#string

Kathy A Gelato

http://www.w3.org/2001/XMLSchema#string

Matthias Busemann

http://www.w3.org/2001/XMLSchema#string

Michael Brands

http://www.w3.org/2001/XMLSchema#string

Pascale Lejeune

http://www.w3.org/2001/XMLSchema#string

P2860

Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor

Structural basis for antagonism and resistance of bicalutamide in prostate cancer

Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations

Regulation of androgen receptor and histone deacetylase 1 by Mdm2-mediated ubiquitylation

Adaptive responses of androgen receptor signaling in castration-resistant prostate cancer

Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome.

A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509.

Overcoming mutation-based resistance to antiandrogens with rational drug design

Androgen receptor antagonists for prostate cancer therapy

Anti-androgens and the mutated androgen receptor of LNCaP cells: differential effects on binding affinity, heat-shock protein interaction, and transcription activation

P304

6015-6028

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.6864

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Klaus Jung

P577

2016-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

290431692

http://www.w3.org/2001/XMLSchema#string

P698

26760770

http://www.w3.org/2001/XMLSchema#string

P932

4868737

http://www.w3.org/2001/XMLSchema#string